$MRNA up 600% YTD — from $29 to $225.
Best performer in the S&P 500 this year.
The rally:
August: +140% in ONE DAY after melanoma vaccine Phase 3 data dropped
September: momentum held, pushed toward $200
Oct 9: +14% on NIH news — accelerating personalized cancer vaccine trials
Cancer vaccine narrative is real. This isn't COVID hype — it's oncology disruption.
If NIH fast-tracks approvals, $MRNA could run harder. Watch for partnership news with pharma giants.
Best performer in the S&P 500 this year.
The rally:
August: +140% in ONE DAY after melanoma vaccine Phase 3 data dropped
September: momentum held, pushed toward $200
Oct 9: +14% on NIH news — accelerating personalized cancer vaccine trials
Cancer vaccine narrative is real. This isn't COVID hype — it's oncology disruption.
If NIH fast-tracks approvals, $MRNA could run harder. Watch for partnership news with pharma giants.